CD38 and plasma cell myeloma: Our results indicated that the population of MEPs (Lin-CD34+CD38+CD45RA−CD123−) was the most significantly suppressed in myeloma patients (n = 20), as shown in Fig. 4A (3.52% ± 0.35% vs. 8.43% ± 0.89%, p < 0.0001).